How to Create a Therapeutics Committee That Is Scientifically and Economically Sound

2004 ◽  
pp. 1-19
Author(s):  
Richard Quintiliani ◽  
Robert A. Quercia
2008 ◽  
Vol 65 (13) ◽  
pp. 1272-1283 ◽  
Author(s):  
Linda S. Tyler ◽  
Sabrina W. Cole ◽  
J. Russell May ◽  
Mirta Millares ◽  
Michael A. Valentino ◽  
...  

2019 ◽  
Vol 6 ◽  
pp. 2329048X1983047
Author(s):  
Edward B. Clark ◽  
Russell J. Butterfield ◽  
Francis M. Filloux ◽  
Joshua L. Bonkowsky

Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is complex. Finally, costs are high, which imposes financial burdens on insurance companies, families, and the health-care system. Our objective was to address challenges for clinical implementation of the new therapeutics. We sought to develop a process that would be personalized for patient and disease, encourage appropriate use of a therapeutic agent while mitigating pressure on a clinician to prescribe the therapy in all instances, and assist third-party payers in approving therapeutic use based on safety and efficacy. We report our creation of a Neurology Therapeutics Committee for pediatric patients. We review the committee’s mechanisms, describe its use and report outcomes, and suggest the Neurology Therapeutics Committee’s broader applicability.


1998 ◽  
Vol 14 (5) ◽  
pp. 202-208
Author(s):  
Isabelle Chabot ◽  
Johanne Morin ◽  
Kateri Bourbeau ◽  
Jocelyne Moisan

Objective: To compare the appropriateness of omeprazole prescriptions in a concurrent drug utilization review (DUR) with the assessed appropriateness of a retrospective DUR. Methods: A retrospective DUR of omeprazole was conducted on prescriptions written from August 23, 1993, to October 8, 1993, in a 340-bed university hospital. This DUR served as a baseline for a concurrent DUR that began on January 27, 1995, and ended on March 16, 1995. The concurrent DUR integrated three steps aimed at improving the quality of omeprazole use: Approval of the criteria by the pharmacology and therapeutics committee of the hospital, distribution of a drug bulletin to all physicians, and a pharmacist's verbal recommendations to physicians whose prescriptions did not meet explicit criteria. Results: Twenty-nine and 64 prescriptions were reviewed in the retrospective and concurrent DURs, respectively. During the concurrent DUR, the pharmacist made 34 verbal recommendations. Of these, 25 (74%) were agreed to by the prescribers. In comparison with the retrospective DUR, the percentage of prescriptions meeting the criteria of indication, combination therapy, and dosage went from 38% to 75% (p < 0.05), from 76% to 95% (p < 0.05), and from 83% to 100% (p > 0.05), respectively, during the concurrent DUR. Conclusions: The concurrent DUR appeared to successfully improve the quality of omeprazole utilization in the hospital.


2003 ◽  
Vol 143 (4) ◽  
pp. 415-421 ◽  
Author(s):  
Thomas A Wilson ◽  
Susan R Rose ◽  
Pinchas Cohen ◽  
Alan D Rogol ◽  
Philippe Backeljauw ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document